Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 4 of 10« First...23456...10...Last »

Democrat Clinton to unveil plan to fight drug price gouging

Democratic presidential candidate Hillary Clinton will unveil a plan this week to cap out-of-pocket costs for specialty drugs, her campaign said on Monday, as a tweet from Clinton accusing companies of “price gouging” sent biotech stocks tumbling.   Clinton was expected to allude to her plan in public remarks on Monday and spell it out […]

Read More »

‘Breakthrough’ drug may not mean what you think

(Reuters Health) – What the Food and Drug Administration calls a ‘breakthrough’ drug is often not the same as what a layperson would call a breakthrough, a new study shows. The FDA uses the term more often, and for smaller advances, than people use it colloquially, and this may lead patients to have unwarranted confidence […]

Read More »

Apples are top fruit for U.S. kids

(Reuters Health) – For U.S. children and teens, more than half of total fruit consumption comes from whole fruits, most commonly apples, new survey data show. “My ultimate goal was to understand what kids are eating,” said lead author Kirsten A. Herrick of the National Center for Health Statistics in Hyattsville, Maryland. “Only about 40 […]

Read More »

Gilead combo drug fights all forms of hep C infection: data

Gilead Sciences Inc said its experimental combination treatment was effective against all forms of hepatitis C infection, citing data from four late-stage studies. The trials were evaluating a once-daily, fixed-dose combination of the drugmaker’s hep C drug, Sovaldi, with velpatasvir, an experimental NS5A inhibitor. The main goal of each study was to achieve a cure, […]

Read More »

ANI Pharma Grabs Two NDAs from Merck & Co. for $75 Million

ANI Pharmaceuticals to Acquire Two NDAs from Merck for $75 Million – Transaction Highlights:– Corticotropin-zinc hydroxide, 40 units/mL, NDA #009854– Assets will be acquired by foreign subsidiary to achieve more favorable tax treatment for ANI– Acquisition significantly advances ANI’s core strategy of re-commercializing previously approved products– Conference call to discuss transaction scheduled today at 10:00am […]

Read More »

Akari, Deciphera Both Nab $75 Million in Financing

NEW YORK — Deciphera Pharmaceuticals and Akari Therapeutics both secured $75 million in funding, which will be used to advance the pipelines of both companies, the companies said in separate statements this morning.   Akari said the $75 million it raised will be used to advance the company’s lead product Coversin, a C5 complement inhibitor, […]

Read More »

Boehringer Ingelheim and BioMed X Apply Crowdsourcing to Establish a Team of Scientists for Identifying Key Epigenetic Regulators of COPD

INGELHEIM and HEIDELBERG, Germany, September 21, 2015 /PRNewswire/ — Aims to identify of novel epigenetic drivers to find new approaches for treating COPD  Crowdsourcing used to find unconventional solutions and identify the best talent from around the world  New research team will be established at the BioMed X Innovation Center in Heidelberg, Germany and sponsored […]

Read More »

A third of Britons born in 2015 will develop dementia: study

One in three people born in Britain in 2015 will develop dementia, according to an analysis commissioned by the charity campaign group Alzheimer’s Research UK. The study, conducted by the Office of Health Economics, shows “a looming national health crisis as the UK population ages”, the charity said, and underlines the need for global efforts […]

Read More »

Merck antibody reduces risk of Clostridium difficile recurrence: study

An experimental antibody developed by Merck & Co Inc was shown in pivotal studies to reduce by about 10 percentage points the risk that infection with Clostridium difficile bacterium, which can cause a deadly diarrhea, will recur. In the United States, C. difficile infects nearly half a million people each year and contributes to around […]

Read More »

High percentage of ex-NFL players had brain disease: report

All but four of 91 former National Football League (NFL) players who donated their brains for research were diagnosed with a disease linked to concussion and head trauma, according to the Concussion Legacy Foundation. The foundation said on its website that the study, conducted by the United States Department of Veteran Affairs and Boston University, […]

Read More »

Roche shows its intent with Switzerland’s tallest skyscraper

Visible from neighboring France and Germany, a new 41-story skyscraper that drugs company Roche opened near the river Rhine on Friday reaches 178 meters into the sky, easily the tallest building in Switzerland. The 550-million Swiss franc ($575 million) tower shows that the company retains its loyalty to the city of Basel where it was […]

Read More »

Bay Area’s ZS Pharma Jumps on Merger Talks, Actelion Stock Drops

Switzerland-based Actelion Ltd. (ALIOF.PK) last week confirmed that it was in talks to acquire ZA Pharma Inc. As a result, the stock dropped about 3.2 percent overnight. ZS Pharma (ZSPH), headquartered in Mateo, Calif., found its stock price jumping 28 percent.   Actelion focuses on pulmonary arterial hypertension (PAH) and markets Veletri, Tracleer and Opsumit. […]

Read More »

McKesson Corporation to Acquire UDG Healthcare’s Pharma Distribution Division for $466 Million

McKesson Announces Agreement to Purchase the Pharmaceutical Distribution Division of UDG Healthcare plc • McKesson to acquire the pharmaceutical distribution division of UDG Healthcare plc for €408 million in cash. • Acquisition will add a leader in pharmaceutical distribution across the Republic of Ireland and Northern Ireland to McKesson’s European business. • The acquisition is […]

Read More »

Novartis hit by China, emerging market slowdown: CEO on CNBC

Drugmaker Novartis has been hit by a slowdown in emerging markets, particularly in China, where previously double-digit growth has decelerated to mid-single digits, Chief Executive Joe Jimenez said in an interview with CNBC on Friday.   Jimenez’ comments echoed concerns expressed on Thursday by U.S. Federal Reserve Chair Janet Yellen, who said the outlook in […]

Read More »

Perrigo recommends shareholders reject Mylan’s tender offer

Generic and over-the-counter drugmaker Perrigo Co on Thursday urged its shareholders to reject Mylan NV’s unsolicited $27 billion tender offer, saying it substantially undervalued the company. Mylan first proposed to buy Perrigo in April and, after being repeatedly rebuffed, launched a tender offer on Monday. It has said it would take control if more than […]

Read More »

Committee backs goal of 1 million for U.S. precision medicine project

The initial goal to recruit 1 million Americans to analyze genetic information as part of the government’s “precision medicine” initiative was approved by an advisory committee to the National Institutes of Health (NIH) on Thursday. The “precision medicine” initiative, announced in January by President Barack Obama, will involve a pool of people – healthy and […]

Read More »

Allergan gets FDA nod for new antipsychotic

Allergan Plc said on Thursday the U.S. Food and Drug Administration approved its new antipsychotic drug to treat bipolar disorder and schizophrenia. The drug, Vraylar, carries a boxed warning on increased risk of death associated with its use in older people with dementia-related psychosis, the FDA said on its website. Vraylar was approved after showing […]

Read More »

Advaxis therapy improves survival rates in cervical cancer patients

Advaxis Inc said its experimental cancer vaccine was found more effective in improving survival rates of cervical cancer patients than standard therapy, validating the technology behind its pipeline of cancer treatments. About 38.5 percent of the patients in a mid-stage study, whose disease had progressed or returned after prior therapy, survived for a year after […]

Read More »

Lilly diabetes drug slashes deaths 32 pct in heart-risk patients

Eli Lilly and Co’s new Jardiance pill slashed deaths by 32 percent in a study of 7,000 patients with type 2 diabetes at risk of heart attack and stroke, a finding that researchers said could make it a mainstay diabetes treatment. “This is the first diabetes therapy to show robust effect in reducing cardiovascular death. […]

Read More »

Mapp Biopharma’s Ebola drug gets FDA fast track status

Mapp Biopharmaceutical Inc said on Thursday that the U.S. Food and Drug Administration granted fast track status to its Ebola drug ZMapp. The FDA grants the status to drugs intended to treat serious conditions that have few or no treatment options and expedites the review of such drugs. ZMapp, which also has an orphan drug […]

Read More »

Page 4 of 10« First...23456...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom